Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

PRESERVE Preventing rejection and ensuring survival of grafts

Coordinator
Institut Pasteur, France
Runs
1 February 2025 to 31 July 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101188820

What the project is doing

In the project's own words, from its summary on CORDIS.

The success of organ transplantation depends on the lifelong use of immunosuppressive drugs to prevent rejection of the donor cells by the recipients immune system. These immunosuppressive drugs have several limitations, most notably major side effects, namely opportunistic infections and cancers. We have recently shown that the bacterial pathogen Listeria monocytogenes (Lm) induces the resistance of infected cells to T-cell mediated killing.

This project aims to protect grafted cells from T cell-mediated killing and thereby mitigate organ rejection. This will lay the groundwork for patent filing and the establishment of a robust business model to ensure further development and clinical translation. This innovative approach is expected to reduce the need for immunosuppressive therapy in transplant recipients, thereby improving outcomes and quality of life for the 130,000 patients who receive transplants worldwide each year.

This proof-of-concept project is based on our recently published study (Maudet et al, Nature 2022) supported by the ERC Invadis grant.

Topics

Who is involved

OrganisationCityCountryRole
Institut PasteurParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI